Johnson & Johnson $JNJ Shares Sold by Hamlin Capital Management LLC

Key Points

• Insider selling: Company insiders sold a total of 30,142 J&J shares worth about $7.36 million in the last three months, including EVP Vanessa Broadhurst (6,197 shares at $243.39) and EVP Timothy Schmid (22,623 shares at $244.33), representing material decreases in their holdings.
• Dividend and fundamentals: J&J paid a $1.30 quarterly dividend ($5.20 annual, yield ~2.2%) with a payout ratio of 47.1%; the company reported $2.46 EPS and $24.28 billion in quarterly revenue, a market cap of ~$582 billion and a P/E of ~21.9.
• Analyst and pipeline momentum: Several analysts raised price targets (e.g., Morgan Stanley $262, RBC $255, BofA $253) leaving a MarketBeat average target of $235.91 ("Moderate Buy"), while recent positives — FDA approval of the TECNIS PureSee IOL and encouraging Phase 1 Erda‑iDRS oncology results — could support near‑term sentiment and medtech/oncology upside.

Hamlin Capital Management LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 0.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 865,870 shares of the company's stock after selling 5,060 shares during the quarter. Johnson & Johnson makes up about 3.7% of Hamlin Capital Management LLC's investment portfolio, making the stock its 17th largest holding. Hamlin Capital Management LLC's holdings in Johnson & Johnson were worth $160,550,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Abich Financial Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter worth about $26,000. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $27,000. Clayton Financial Group LLC acquired a new stake in Johnson & Johnson during the third quarter worth about $28,000. Semmax Financial Advisors Inc. lifted its holdings in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after acquiring an additional 72 shares during the last quarter. Finally, Compass Financial Services Inc boosted its stake in Johnson & Johnson by 707.1% in the third quarter. Compass Financial Services Inc now owns 226 shares of the company's stock valued at $42,000 after acquiring an additional 198 shares during the period. Institutional investors own 69.55% of the company's stock.

Insider Activity

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the business's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 22,623 shares of the company's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the sale, the executive vice president directly owned 26,769 shares of the company's stock, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Down 0.1%

JNJ opened at $241.71 on Monday. The stock's 50 day moving average price is $231.91 and its 200 day moving average price is $206.65. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The stock has a market cap of $582.19 billion, a P/E ratio of 21.87, a P/E/G ratio of 2.38 and a beta of 0.34. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson's dividend payout ratio is currently 47.06%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approves the TECNIS PureSee intraocular lens, adding a new, differentiated cataract/presbyopia product to J&J’s surgical vision portfolio — could support revenue and aftermarket growth in the medtech segment. FDA Approval Of TECNIS PureSee IOL Adds New Lens For J&J Investors
• Positive Sentiment: Promising Phase 1 Erda‑iDRS (erdafitinib) results in intermediate‑risk NMIBC: 89% complete response rate and durable responses up to 18 months with tolerable safety — bolsters oncology pipeline optionality if later‑stage data confirm benefit. Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
• Positive Sentiment: BofA raised its price target (to $253) and lifted revenue expectations citing pipeline growth — supportive analyst attention that can underpin sentiment even with a Neutral rating. BofA Raises Johnson & Johnson (JNJ) Price Target on Pipeline Growth
• Positive Sentiment: Citigroup analyst expects JNJ shares to rise — additional buy-side commentary can amplify positive flows if confirmed with upgrades or higher targets. Johnson & Johnson NYSE: JNJ Stock Price Expected to Rise, Citigroup Analyst Says
• Neutral Sentiment: Dividend and “Dividend King” coverage reminds investors of JNJ’s income profile — supportive for long‑term holders but unlikely to drive short‑term price swings. Johnson & Johnson (JNJ) Could Be a Great Choice
• Neutral Sentiment: Barclays reaffirmed its Hold rating — steady analyst stance that tempers upside momentum from positive news. Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)
• Neutral Sentiment: Industry pieces on BCG shortages and competitor ImmunityBio note market dynamics in NMIBC — useful context for future demand shifts but not an immediate JNJ catalyst. IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking
• Neutral Sentiment: Analyst / valuation updates show modest shifts in fair value assumptions tied to individual drugs (Tremfya, Tecvayli, Inlexzo, Darzalex) — indicates ongoing re‑rating risk/reward as pipeline readouts arrive. How The Johnson & Johnson (JNJ) Narrative Is Shifting With Pipeline Rethinks And New Valuation Targets
• Negative Sentiment: Preliminary approval of a $65M eve‑of‑trial settlement in an antitrust suit tied to Actelion’s Tracleer — modest direct financial hit but reputational/legal overhang for the pharma legacy business. Eve-of-Trial $65M Settlement Preliminarily Approved in Novel Antitrust Class Action Against J&J Subsidiary Actelion Pharmaceuticals

Analysts Set New Price Targets

A number of analysts have recently weighed in on JNJ shares. Weiss Ratings reiterated a "buy (b)" rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Sanford C. Bernstein upped their price objective on Johnson & Johnson from $208.00 to $225.00 and gave the stock a "market perform" rating in a research note on Friday, January 23rd. Royal Bank Of Canada increased their target price on Johnson & Johnson from $240.00 to $255.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 3rd. Morgan Stanley set a $262.00 price target on shares of Johnson & Johnson and gave the company an "overweight" rating in a report on Wednesday, January 28th. Finally, Rothschild & Co Redburn increased their price objective on shares of Johnson & Johnson from $180.00 to $210.00 and gave the stock a "neutral" rating in a report on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $235.91.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.